Safety and Effects of Football in Skeletal Metastatic Prostate Cancer: a Subgroup Analysis of the FC Prostate Community Randomised Controlled Trial

Eik Dybboe Bjerre1,*, Sarah Weller2, Mads Hvid Poulsen3, Søren Sørensen Madsen4, Rie Dybboe Bjerre5, Peter Busch Østergren6, Michael Borre7, Klaus Brasso8 and Julie Midtgaard1,9

Abstract

Background: Skeletal metastatic disease excludes many cancer patients from participating in exercise and physical activity due to safety concerns. Empirical evidence from high-quality trials is warranted to guide clinicians and patients.

Objective: To evaluate the safety and potential benefits of high-impact aerobic exercise in patients with prostate cancer with skeletal metastases.

Design: Exploratory subgroup analysis of a pragmatic, multicentre, parallel randomised controlled trial.

Setting: The trial recruited 214 patients from five hospital urological departments in Denmark.

Participants: Patients with prostate cancer with skeletal metastases (n = 41).

Intervention: Six months of football training twice weekly at a local club or usual care. Both groups received brief information on physical activity recommendations at the time of randomisation.

Main Outcome(s) and Measure(s): Safety, defined as falls, fractures and hospital admissions. Effects were evaluated on the primary outcome (prostate cancer-specific quality of life) and secondary outcomes (lean body mass, fat mass, hip and spine bone mineral density, and general physical and mental health).

Results: The original trial comprised 214 participants, 41 of whom had skeletal metastases at enrolment. Of these, 22 were allocated to football and 19 to usual care. The trial retention rate was 95% at 12 weeks and 88% at 6 months. Football participants attended 13 sessions on average at 12 weeks and 23 at 6 months. There were two falls, one in each group after 6 months, and no fractures. There were four unplanned hospital admissions in the study period, all four in the usual care group. Statistically significant between-group difference was observed in the primary outcome change in prostate cancer-specific quality of life at 12 weeks (7.6 points [95% CI 0.5 to 15.0]; P = 0.038). No statistical changes were found in the secondary outcomes.

(Continued on next page)
Conclusion: The analysis showed that football training was safe in patients with skeletal metastatic prostate cancer and significantly improved quality of life. Larger analyses and/or trials are warranted to confirm the safety of exercise more broadly in cancer patients with skeletal metastatic disease.

Trial Registration: ClinicalTrials.gov, NCT02430792. Date of registration 30 April 2015

Keywords: Soccer, Cancer survivor, Community, Exercise, Rehabilitation

Key Points

- This study aimed to investigate whether high-impact aerobic exercise, such as football, is safe in patients with prostate cancer with skeletal metastases.
- The analysis of this pragmatic randomised controlled trial in patients with prostate cancer with skeletal metastases showed that fewer adverse events occurred in the patients playing football compared to those undergoing usual care. Likewise, prostate cancer-specific quality of life improved for the men in the football group compared to those in the usual care group.
- The results suggest that men with skeletal metastatic prostate cancer should not be excluded from exercise and some can even engage in strenuous, high-impact exercise.

Background

Survival rates in advanced cancer have increased due to treatment advances, as has the number of people living with adverse treatment side effects, including fatigue, emotional distress and decreased physical functioning [1]. Exercise has been identified as an effective strategy that may ameliorate negative treatment side effects and improve physical function [2]. A majority of men with advanced prostate cancer (PCa) develop bone metastases and may experience pain and subsequent skeletal complications such as pathological fracture or spinal cord compression, functional limitations and reduced quality of life (QoL) [3–5]. Globally, cancer exercise guidelines recommend that individuals with bone metastases should avoid inactivity and perform both aerobic and resistance exercises [6, 7]. Despite this, only two randomised controlled trials (RCTs) have evaluated exercise in PCa patients who all have skeletal metastases [8, 9]. These two studies purposely avoided specific loading to the sites of the skeletal metastases. We conducted what is currently the largest RCT evaluating supervised exercise in men with PCa [10, 11]. In the overall study population, mental health, measured using the 12-Item Short Form Health Survey (SF-12), improved by 3.0 points, although no effect was found in relation to PCa-specific QoL. Our analysis showed that in participants playing football, fat mass decreased, lean body mass remained unchanged and hip bone mineral density showed minor improvement (0.008 g/cm²) [10].

As safety is a concern in patients with skeletal metastasis, the objective of this subgroup analysis is to further evaluate the potential safety and effects of unrestricted physical exercise, such as football training, in patients with skeletal metastatic prostate cancer (mPCa).

Methods

An exploratory subgroup analysis was performed of a pragmatic multicentre RCT conducted at five centres in Denmark between 2015 and 2018 that has been previously described in detail [12]. Participants were randomly allocated 1:1 to either community-based football (FG) 1 h, twice weekly for 6 months, or usual care (UC). Patients eligible for study inclusion were diagnosed with PCa and able to complete questionnaires in Danish. All participants provided informed written consent prior to participation, and the trial was conducted in accordance with the Declaration of Helsinki. Patients were excluded if they had undergone prostatectomy within the last 6 weeks and had a hip or spine t-score below 2.5. No formal screening was done for painful skeletal metastases, spinal cord compression or cauda equina syndrome at enrolment. However, possible participants were asked to consider if they or their treating physician had advised them to avoid exercise. This subgroup analysis only included patients with skeletal mPCa at enrolment.

Intervention

The intervention is described in detail in the protocol [12]. However, in relation to increasing the safety of football in patients with prostate cancer with skeletal metastases (including minimising the risk of injuries), it should be noted here that the intervention consisted of 20 min of warm-up (i.e. running, own bodyweight and partner exercises), 20 min of football skill training and 20 min of regular football match play.

Outcomes

Safety was evaluated using three outcomes: falls resulting in seeking medical assistance, fractures and hospital admissions. The accuracy of these outcomes reported by patients was verified through a review of hospital records.
Effects were evaluated using PCa-specific QoL assessed using the Functional Assessment of Cancer Therapy-Prostate (FACT-P) questionnaire, mental and physical health assessed with SF-12 and body composition (lean body mass and fat mass) and bone mineral density (hip and spine) assessed using dual-energy X-ray absorptiometry.

An exploratory outcome was disease progression, defined by either doubling of prostate-specific antigen or

| Table 1 Participant characteristics | Football (n = 22) | Usual care (n = 19) | Total (n = 41) |
|------------------------------------|------------------|--------------------|---------------|
| Age (years)                        | 68.9 (8.4)       | 67.3 (7.0)         | 68.2 (7.7)    |
| Employment status                  |                  |                    |               |
| Paid work                          | 6 (27%)          | 4 (21%)            | 10 (24%)      |
| Retired                            | 16 (73%)         | 15 (79%)           | 31 (76%)      |
| Education                          |                  |                    |               |
| No education                       | 3 (14%)          | 0 (0%)             | 3 (7%)        |
| Lower secondary education (9th/10th grade) | 1 (5%)    | 1 (5%)             | 2 (5%)        |
| Vocational education               | 6 (27%)          | 7 (37%)            | 13 (32%)      |
| Upper secondary education (12th grade) | 2 (9%)    | 2 (11%)            | 4 (10%)       |
| College or higher                  | 10 (45%)         | 9 (47%)            | 19 (46%)      |
| Marital status                     |                  |                    |               |
| Married or living with partner     | 17 (77%)         | 17 (89%)           | 34 (83%)      |
| Others (single, divorced, widowed) | 5 (23%)          | 2 (11%)            | 7 (17%)       |
| Time since diagnosis, days         | 1099 (941)       | 1152 (953)         | 1123 (935)    |
| ISUP Gleason grading (score)       |                  |                    |               |
| Group 2 (3 + 4)                     | 3 (14%)          | 2 (11%)            | 5 (12%)       |
| Group 3 (4 + 3)                     | 2 (9%)           | 4 (21%)            | 6 (15%)       |
| Group 4 (8)                        | 4 (18%)          | 3 (16%)            | 7 (17%)       |
| Group 5 (9–10)                     | 13 (59%)         | 8 (42%)            | 21 (51%)      |
| Not known                          | 0 (0%)           | 2 (11%)            | 2 (5%)        |
| Treatment at baseline              |                  |                    |               |
| Current                            |                  |                    |               |
| Anti-androgen monotherapy          | 1 (5%)           | 1 (5%)             | 2 (5%)        |
| Castration (surgical or pharmacological) | 21 (95%) | 18 (95%)           | 39 (95%)      |
| Previous or current chemotherapy (docetaxel) | 9 (47%) | 7 (32%)             | 16 (39%)      |
| Number of co-morbidities           |                  |                    |               |
| Zero                               | 6 (27%)          | 9 (47%)            | 15 (37%)      |
| One                                | 4 (18%)          | 3 (16%)            | 7 (17%)       |
| Two                                | 6 (27%)          | 3 (16%)            | 9 (22%)       |
| Three or more                      | 6 (27%)          | 4 (21%)            | 10 (24%)      |
| Bone lesion site                   |                  |                    |               |
| Pelvis                             | 16 (73%)         | 9 (47%)            | 25 (61%)      |
| Femur                              | 2 (9%)           | 5 (26%)            | 7 (17%)       |
| Rib/thoracic spine                 | 11 (50%)         | 10 (53%)           | 21 (51%)      |
| Lumbar spine                       | 8 (36%)          | 3 (16%)            | 11 (27%)      |
| Humerus                            | 0 (0%)           | 1 (5%)             | 1 (2%)        |
| All regions                        | 2 (9%)           | 3 (16%)            | 5 (12%)       |
| Other sites                        | 0 (0%)           | 1 (5%)             | 1 (2%)        |
| Unknown                            | 0 (0%)           | 3 (16%)            | 3 (7%)        |

ISUP International Society of Urological Pathology
Data are mean (standard deviation) or n (%)
radiologically verified disease progression based on the review of hospital records.

Statistical Analyses
All analyses were conducted as described in the protocol, with the primary outcome evaluated after 12 weeks and a study period from baseline to 6 months [12]. Effect outcomes were estimated using analysis of covariance that included the baseline value of the outcome and age as a covariate (adjustment). Changes are presented as marginal mean differences between allocation groups with 95% confidence intervals (CIs). Safety outcomes and progression were summarised using descriptive statistics. Fischer’s exact test was used to compare differences between allocation groups. All analyses were conducted with Stata 15.1 (StataCorp LLC, College Station, TX, USA).

Results
Between June 2015 and February 2017, 214 participants were randomised [10, 11], 41 of whom (FG (n = 22) and UC (n = 22)) had skeletal mPCA. Table 1 presents participant characteristics. To our knowledge, no participants had painful skeletal metastases, spinal cord compression or cauda equina syndrome.

Retention for the 41 patients with skeletal metastatic disease was 95% at 12 weeks (FG = 95%, UC = 95%) and 88% at 6 months (FG = 91%, UC = 84%) (Fig. 1). Median attendance in FG from baseline to 12 weeks was 13 sessions (interquartile ratio 10, 63%). From baseline to 6 months, it was 23 sessions (interquartile ratio 23, 54%). On average, football sessions lasted 58.8 min, see further details [10].

Outcomes
Table 2 presents the safety outcomes for the adverse events that occurred in the two groups from baseline to 6 months. No significant differences were found between groups, although UC had four hospital admissions and FG had none ($P = 0.078$).

Table 3 summarises mean changes for primary and secondary outcomes (see Additional file 1). As shown, the primary outcome, PCA-specific QoL, was significantly higher for FG compared to UC at 12 weeks, with a 7.6-point difference (95% CI, 0.5 to 15.0; $P = 0.038$). No statistically significant changes were found in the secondary outcomes. Exploratory analysis found disease

![Fig. 1 Flow of participants. DXA dual-energy X-ray absorptiometry, Pca prostate cancer, () DXA lost to follow-up](image-url)
progression in 25 out of 41 patients, with significantly more cases of disease progression in UC (16 patients out of 19) compared to FG (9 out of 22; \( P = 0.009 \)).

**Discussion**

Our subgroup analysis on mPCa patients participating in the FC Prostate Community Trial showed that the risk of falls, fractures and hospital admissions was not higher in FC compared to UC. This indicates that physical exercise alone does not pose a threat in men with skeletal metastatic lesions and can improve physical function and QoL. Notably, the magnitude of difference in PCa-specific QoL between the two groups is > 6 points, which is the established minimum clinically important difference in patients with advanced PCa [13]. In line with our results, Cheville et al., who evaluated exercise delivered as telerehabilitation with 264 participants (51%) with bone metastases, found significant positive effects on QoL [14]. Additionally, both studies found reduced hospital utilisation (e.g. reduced length of stay or fewer hospital admissions) when all of the participants were analysed [11, 14].

The benefits of the intervention on QoL reported in the current study were not found in our primary analysis, which included participants without metastatic disease, indicating that football may be a way to increase

**Table 3** Effect outcomes

|                      | Football group (n = 22)                                                                 | Usual care group (n = 19)                                                                 | Covariance analysis, difference between groups, mean (95% CI) | Adjusted for age and baseline score | \( P \)-value |
|----------------------|---------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------|-----------------------------------|---------------|
| Change in prostate cancer-specific quality of life (points, higher is better) |                                                                                                                                  |                                                                                                                                  |                                                                                    |                                  |               |
| 12 weeks             | \( n = 21 \) \( \text{Mean change (95\% CI)} = -1.8 (-6.8 to 3.3) \)                                                                 | \( n = 18 \) \( \text{Mean change (95\% CI)} = -9.0 (-14.4 to -3.5) \)                                                                 | \( 7.6 (0.5 to 15.0) \)                                                                 | \( 0.038 \) |                   |
| 6 months             | \( n = 20 \) \( \text{Mean change (95\% CI)} = -5.5 (-10.6 to -0.4) \)                                                                 | \( n = 16 \) \( \text{Mean change (95\% CI)} = -5.8 (-11.5 to -0.1) \)                                                                 | \( 0.5 (-7.3 to 8.4) \)                                                                 | \( 0.895 \) |                   |
| Change in lean body mass (kilogrammes) |                                                                                                                                  |                                                                                                                                  |                                                                                    |                                  |               |
| 6 months             | \( n = 21 \) \( \text{Mean change (95\% CI)} = -0.3 (-1.1 to 0.5) \)                                                                 | \( n = 15 \) \( \text{Mean change (95\% CI)} = -0.4 (-1.3 to 0.6) \)                                                                 | \( -0.2 (-1.4 to 0.9) \)                                                                 | \( 0.673 \) |                   |
| Change in fat mass (kilogrammes) |                                                                                                                                  |                                                                                                                                  |                                                                                    |                                  |               |
| 6 months             | \( n = 21 \) \( \text{Mean change (95\% CI)} = -0.4 (-1.3 to 0.6) \)                                                                 | \( n = 15 \) \( \text{Mean change (95\% CI)} = -0.2 (-1.4 to 1.0) \)                                                                 | \( 0.4 (-1.1 to 1.8) \)                                                                 | \( 0.610 \) |                   |
| Change in total hip bone mineral density (g/cm²) |                                                                                                                                  |                                                                                                                                  |                                                                                    |                                  |               |
| 6 months             | \( n = 21 \) \( \text{Mean change (95\% CI)} = 0.007 (-0.025 to 0.039) \)                                                                 | \( n = 15 \) \( \text{Mean change (95\% CI)} = 0.039 (0.001 to 0.078) \)                                                                 | \( -0.028 (-0.083 to 0.026) \)                                                                 | \( 0.295 \) |                   |
| Change in lumbar spine L1–L4 bone mineral density (g/cm²) |                                                                                                                                  |                                                                                                                                  |                                                                                    |                                  |               |
| 6 months             | \( n = 21 \) \( \text{Mean change (95\% CI)} = 0.045 (-0.005 to 0.096) \)                                                                 | \( n = 15 \) \( \text{Mean change (95\% CI)} = 0.017 (-0.042 to 0.077) \)                                                                 | \( 0.029 (-0.055 to 0.113) \)                                                                 | \( 0.487 \) |                   |
| Change in general physical health (SF-12) |                                                                                                                                  |                                                                                                                                  |                                                                                    |                                  |               |
| 12 weeks             | \( n = 21 \) \( \text{Mean change (95\% CI)} = -2.0 (-4.9 to 0.9) \)                                                                 | \( n = 18 \) \( \text{Mean change (95\% CI)} = -3.7 (-6.8 to -0.6) \)                                                                 | \( 1.9 (-2.4 to 6.2) \)                                                                 | \( 0.384 \) |                   |
| 6 months             | \( n = 20 \) \( \text{Mean change (95\% CI)} = -3.3 (-7.4 to 0.7) \)                                                                 | \( n = 16 \) \( \text{Mean change (95\% CI)} = -3.7 (-8.3 to 0.8) \)                                                                 | \( 0.3 (-6.0 to 6.7) \)                                                                 | \( 0.912 \) |                   |
| Change in general mental health (SF-12) |                                                                                                                                  |                                                                                                                                  |                                                                                    |                                  |               |
| 12 weeks             | \( n = 21 \) \( \text{Mean change (95\% CI)} = 0.1 (-3.1 to 3.2) \)                                                                 | \( n = 18 \) \( \text{Mean change (95\% CI)} = -2.0 (-5.4 to 1.4) \)                                                                 | \( 1.9 (-2.6 to 6.4) \)                                                                 | \( 0.402 \) |                   |
| 6 months             | \( n = 20 \) \( \text{Mean change (95\% CI)} = -2.4 (-6.3 to 1.4) \)                                                                 | \( n = 16 \) \( \text{Mean change (95\% CI)} = -2.9 (-7.4 to 1.6) \)                                                                 | \( 0.1 (-5.9 to 6.1) \)                                                                 | \( 0.976 \) |                   |

SF-12 12-item Short Form Health Survey
QoL in men with advanced PCa only. However, it could also indicate that FACT-P may be a more suitable outcome measure and may have higher responsiveness in patients with advanced disease. In comparison, a previous study by Segal et al. showed that participants treated with palliative intent (i.e. patients with advanced/metastatic disease) reported a difference of 5.7 points on FACT-P and also showed larger effects in comparison to men treated with curative intent [15].

The major limitation of this subgroup analysis is that the number of patients is low. Albeit limited by the number of patients and events, the analysis did not indicate that physical exercise increases the risk of injury and hospitalisation in men with skeletal metastases. The reported difference in disease progression favouring FG should be interpreted with caution as the finding can be spurious, and the outcome was exploratory. Moreover, the sample size is small. Lastly, because patients with unstable and/or painful skeletal metastasis likely did not participate in this trial due to self-exclusion or the exclusion criteria, the results cannot be generalised to this population. Further research should focus on the safety aspects of exercise modalities or modifying them for cancer patients with skeletal metastatic disease, the presence of osteoporosis or skeletal pain treated with opioids, which often precludes patients from engaging in exercises. Stability and size of metastases should be explored in future studies to further evaluate the effects of the loading during exercise.

Conclusions

In this study, the patients with skeletal mPCa enrolled in a physical exercise programme experienced better QoL without increased adverse events, which indicates that high-impact, community-based aerobic exercise in this clinical subgroup is safe. Based on these findings, trials are warranted to confirm the safety of exercise more broadly in cancer patients with skeletal metastatic disease.

Abbreviations

CI: Confidence interval; FACT-P: Functional Assessment of Cancer Therapy-Prostate; ISUP: International Society of Urological Pathology; mPCa: Metastatic prostate cancer; PCa: Prostate cancer; QoL: Quality of life; RCT: Randomised controlled trial; SF-12: 12-Item Short Form Health Survey

Supplementary Information

The online version contains supplementary material available at https://doi.org/10.1186/s40798-021-00318-6.

Additional file 1: Supplementary Table 1. Means of outcomes at baseline, 12 weeks and 6 months

Acknowledgements

This study was funded by a grant from TrygFonden (ID106471). The authors thank the study participants.

Authors’ Contributions

Eik Dybboe Bjerre, Klaus Brasso and Julie Midtgaard initiated the study idea and planned the data collection. Mads Hvid Poulsen, Søren Sørensen Madsen, Peter Busch Østergren, Michael Borre and Klaus Brasso were involved in the data collection. Eik Dybboe Bjerre, Julie Midtgaard and Rie Dybboe Bjerre contributed to the data analysis. Eik Dybboe Bjerre wrote the first draft. Sarah Weller, Mads Hvid Poulsen, Søren Sørensen Madsen, Rie Dybboe Bjerre, Peter Busch Østergren, Michael Borre, Klaus Brasso and Julie Midtgaard (all authors) critically revised it and approved the final version.

Funding

TrygFonden funded the study but played no role in the study design, data collection, data analysis, data interpretation or writing of the report.

Availability of Data and Materials

Please contact the corresponding author for data requests.

Declarations

Ethics Approval and Consent to Participate

The FC Prostate Community Trial was approved by the National Committee on Health Research Ethics (file no. H-2-2014-099). All participants provided written informed consent prior to participation in the study.

Consent for Publication

Not applicable.

Competing Interests

The authors, Eik Dybboe Bjerre, Sarah Weller, Mads Hvid Poulsen, Søren Sørensen Madsen, Rie Dybboe Bjerre, Peter Busch Østergren, Michael Borre, Klaus Brasso, and Julie Midtgaard, declare that they have no competing interests.

Author details

1The University Hospitals Centre for Health Research, University of Copenhagen, Rigshospitalet, Department 9701, Blegdamsvej 9, 2100 Copenhagen, Denmark. 2Prostate Cancer Supportive Care Program, Vancouver Prostate Centre, Vancouver, Canada. 3Department of Urology and Academy of Geriatric Cancer Research, Odense University Hospital, Odense, Denmark. 4Department of Urology, Hospital of South West Jutland, Esbjerg, Denmark. 5Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark. 6Department of Urology, Herlev and Gentofte Hospital, Herlev, Denmark. 7Department of Urology, Aarhus University Hospital, Aarhus, Denmark. 8Copenhagen Prostate Cancer Center, Department of Urology, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark. 9Department of Public Health, University of Copenhagen, Copenhagen, Denmark.

Received: 2 October 2020 Accepted: 31 March 2021

Published online: 20 April 2021

References

1. Miller KD, Nogueira L, Mariotto AB, Rowland JH, Yabroff KR, Alfano CM, et al. Cancer treatment and survivorship statistics, 2019: CA Cancer J Clin. 2019; 69(5):363–85. https://doi.org/10.3322/caac.21565.

2. Campbell KL, Winters-Stone KM, Wiskemann J, May AM, Schwartz AL, Courneya KS, et al. Exercise guidelines for cancer survivors: consensus statement from international multidisciplinary roundtable. Med Sci Sports Exerc. 2019;51(11):2375–90. https://doi.org/10.1249/MSS.0000000000002116.

3. Saad F, Olsson C, Schulman CC. Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care. Eur Urol. 2004;46(6):731–9; discussion 9-40. https://doi.org/10.1016/j.eururo.2004.08.016.

4. Higano CS. Understanding treatments for bone loss and bone metastases in patients with prostate cancer: a practical review and guide for the clinician. Urol Clin North Am. 2004;31(2):331–52. https://doi.org/10.1016/j.ucc.2004.01.001.

5. Litwin MS, Tan H-J. The diagnosis and treatment of prostate cancer: a review. JAMA. 2017;317(24):2532–42. https://doi.org/10.1001/jama.2017.7248.

6. Rock CL, Doyle C, Demark-Wahnefried W, Meyerhardt J, Courneya KS, Schwartz AL, et al. Nutrition and physical activity guidelines for cancer
survivors. CA Cancer J Clin. 2012;62(4):243–74. https://doi.org/10.3322/caa c.21142.
7. Schmitz KH, Courneya KS, Matthews C, Demark-Wahnefried W, Galvao DA, Pinto BM, et al. American College of Sports Medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc. 2010;42(7): 1409–26. https://doi.org/10.1249/MSS.0b013e3181e0c112.
8. Cormie P, Newton RU, Spyr N, Joseph D, Taaffe DR, Galvão DA. Safety and efficacy of resistance exercise in prostate cancer patients with bone metastases. Prostate CancerProstatic Dis. 2013;16(4):328–35. https://doi.org/1 0.1038/pcan.2013.22.
9. Galvao DA, Taaffe DR, Spyr N, Cormie P, Joseph D, Chambers SK, et al. Exercise preserves physical function in prostate cancer patients with bone metastases. Med Sci Sports Exerc. 2018;50(3):393–9. https://doi.org/10.1249/ MSS.0000000000001454.
10. Bjerre ED, Brasso K, Jorgensen AB, Petersen TH, Eriksen AR, Tolver A, et al. Football compared with usual care in men with prostate cancer (FC Prostate Community Trial): a pragmatic multicentre randomized controlled trial. Sports Med. 2018;49:45–58.
11. Bjerre ED, Petersen TH, Jørgensen AB, Johansen C, Krustup P, Langdahl B, et al. Community-based football in men with prostate cancer: 1-year follow-up on a pragmatic, multicentre randomised controlled trial. PLoS Med. 2019;16(10):e1002936. https://doi.org/10.1371/journal.pmed.1002936.
12. Bjerre E, Bruun DM, Tolver A, Brasso K, Krustup P, Johansen C, et al. Effectiveness of community-based football compared to usual care in men with prostate cancer: protocol for a randomised, controlled, parallel group, multicenter superiority trial (The FC Prostate Community Trial). BMC Cancer. 2016;16(1):767. https://doi.org/10.1186/s12885-016-2805-0.
13. Cella D, Nichol MB, Eton D, Nelson JB, Mulani P. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy—Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health. 2009;12(1):124–9.
14. Cheville AL, Moynihan T, Herrin J, Loprinzi C, Kronen K. Effect of collaborative telerehabilitation on functional impairment and pain among patients with advanced-stage cancer: a randomized clinical trial. JAMA Oncol. 2019;5(3):544–52. https://doi.org/10.1001/jamaoncol.2019.0011.
15. Segal RJ, Reid RD, Courneya KS, Malone SC, Parliament MB, Scott CG, et al. Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2003;21(9):1653–9. https://doi.org/10.1200/ JCO.2003.09534.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Submit your manuscript to a SpringerOpen journal and benefit from:
► Convenient online submission
► Rigorous peer review
► Open access: articles freely available online
► High visibility within the field
► Retaining the copyright to your article

Submit your next manuscript at ► springeropen.com